Ipamorelin
- Fat loss & metabolism
- Growth hormone
- Recovery & repair
The selective growth hormone peptide — a GH pulse without the ACTH and cortisol rise the older secretagogues bring.
Read the published research →What Ipamorelin does
Ipamorelin is a five-amino-acid ghrelin-receptor agonist from Novo Nordisk, and selectivity is the whole point: it matched GHRP-6 for growth hormone release, 65 against 74 ng/mL at peak, without pushing ACTH or cortisol above the level GHRH alone produces, where GHRP-6 and GHRP-2 raised both. In 40 healthy men it behaved briefly and cleanly, producing a single episode of growth hormone release that peaked within the first hour and fell back to negligible concentrations, with a two-hour terminal half-life. The rest of the signal is in bone and body composition: tibial growth rate rose from 42 micrometres a day on vehicle to 52 in the highest-dose group, and against a glucocorticoid alone it produced a four-fold higher periosteal bone formation rate and stronger calf-muscle contraction. Not all of it points where buyers expect — body weight rose about 15% at two weeks with fat mass up relative to body weight, the opposite of what growth hormone itself did in the same animals — and that work is in rats and mice. In the phase 2 trial, which missed its endpoint in 114 adults recovering from bowel surgery, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm against 94.8% on placebo.
- Growth hormone pulses without the cortisol bump
- Lean mass and training recovery
- Sleep quality and overnight repair
- Bone strength and joint resilience
- Appetite and body composition
- Age-related decline in growth hormone
Common areas of interest, not measured results. The findings below are the published data.
In a multicentre, double-blind, placebo-controlled phase 2 trial in 114 adults after small or large bowel resection, median time from first dose to tolerating a standardised solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, which did not reach statistical significance (p = 0.15). No secondary efficacy endpoint separated from placebo.3
In 40 healthy men given five ascending intravenous infusion rates, ipamorelin showed dose-proportional pharmacokinetics: terminal half-life 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. It produced a single episode of growth hormone release peaking at 0.67 hours and declining to negligible concentrations at every dose level; half-maximal GH stimulation occurred at 214 nmol/L.11
In growth-hormone-deficient lit/lit mice and GH-intact littermates, ipamorelin raised body weight by about 15% at two weeks and increased fat pad weight relative to body weight in both genotypes, whereas growth hormone itself reduced relative fat mass in lit/lit mice, so the adiposity effect does not require GH. Serum leptin and food intake rose in GH-intact mice.9
For laboratory research use only. Not a drug, food, or cosmetic. Not for human or veterinary use, ingestion, or any form of consumption. Sold exclusively to qualified researchers.
